2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

NCT02916056 | Terminated Phase 3 Results DMC FDA Drug

• 1 other identifier: TTP488-303
• Study Type: interventional
• Target: 297
• Locations: 2 countries
• Sites: 71

Brief Summary

This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.

Conditions

Alzheimer's Disease

Keywords

Alzheimer's disease; RAGE; ADAS-cog; CDR-sb

Outcome Measures

Primary Outcomes (1)

• Number of Subjects With at Least One Treatment-Emergent Adverse Event

  up to 18 months

Study Arms (1)

Azeliragon 5 mg

EXPERIMENTAL

Azeliragon (TTP488) 5mg orally once daily for 2 years

Drug: Azeliragon 5mg

Interventions

Azeliragon 5mg DRUG

Also known as: TTP488

Azeliragon 5 mg

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Successful completion of Study TTP488-301 through the Month 18 Visit without ongoing serious adverse events or history of serious adverse drug reactions during study TTP488-301.
• Patients must enroll in the present study within 7 days of completion of study TTP488-301.
• Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally authorized representative) and caregiver/informant has been informed of all pertinent aspects of the study. Participants must be able to provide assent (where this is in accordance with local laws, regulations and ethics committee policy) and assent may be re-evaluated during the study at regular intervals.
• Participants and caregiver/informants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• The subject must have a reliable caregiver/informant with regular contact (i.e., 10 hours a week as combination of face-to-face visits and telephone contact acceptable) who will facilitate the subject's full participation in the study. Caregivers/informant must have sufficient subject interaction to be able to provide meaningful input into the rating scales administered in this study where caregiver/informant input is required, in particular the CDR and evidence of this should be documented in source documentation. Participants who reside in assisted living facilities are permitted provided that they meet caregiver/informant criteria.
• Participants and caregiver/informants must be able to read, write, and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate psychometric testing.
• Subject must be able to ingest oral medications.

You may not qualify if:

• Subjects with serious suicide risk. If there are "yes" answers on items 4, 5 or on any behavioral question of the C-SSRS, a suicide risk assessment must be done by a qualified mental health professional with expertise in the evaluation of suicidality in the elderly (e.g., psychiatrist, geriatrician or neurologist specializing in treatment of patients with AD) to determine whether it is safe for the subject to participate in the study.
• Subjects demonstrating a QTcF \> 480 msec or a \>45 msec change from the TTP488-301 Baseline value based on the locally read ECG performed at the TTP488-301 Month 18 Visit (TTP488-303 Baseline). Participants with known history of bundle branch block (either right or left) are allowed if absolute QTcF value does not exceed 500 msec. Participants with a functioning pacemaker, indicated by an ECG displaying paced rhythm, are allowed with no QTc upper limit.
• Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may prevent the subject from completing the 2-year study or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

Sponsors & Collaborators

• vTv Therapeutics: lead

Study Sites (71)

Unknown Facility

Phoenix, Arizona, 85004, United States

Location

Unknown Facility

Phoenix, Arizona, 85013, United States

Location

Unknown Facility

Tucson, Arizona, 85724, United States

Location

Unknown Facility

Bellflower, California, 90706, United States

Location

Unknown Facility

Costa Mesa, California, 92626, United States

Location

Unknown Facility

Fullerton, California, 92835, United States

Location

Unknown Facility

Glendale, California, 91206, United States

Location

Unknown Facility

Imperial, California, 92251, United States

Location

Unknown Facility

Irvine, California, 92614, United States

Location

Unknown Facility

Laguna Hills, California, 92653, United States

Location

Unknown Facility

Long Beach, California, 90806, United States

Location

Unknown Facility

Riverside, California, 92506, United States

Location

Unknown Facility

San Bernardino, California, 92408, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

Atlantis, Florida, 33462, United States

Location

Unknown Facility

Delray Beach, Florida, 33445, United States

Location

Unknown Facility

Hallandale, Florida, 33009, United States

Location

Unknown Facility

Hialeah, Florida, 33016, United States

Location

Unknown Facility

Jacksonville, Florida, 32216, United States

Location

Unknown Facility

Lake Worth, Florida, 33449, United States

Location

Unknown Facility

Miami, Florida, 33122, United States

Location

Unknown Facility

Miami, Florida, 33137, United States

Location

Unknown Facility

Miami Beach, Florida, 33140, United States

Location

Unknown Facility

Miami Lakes, Florida, 33014, United States

Location

Unknown Facility

Orlando, Florida, 32806, United States

Location

Unknown Facility

Sarasota, Florida, 34243, United States

Location

Unknown Facility

Sunrise, Florida, 33351, United States

Location

Unknown Facility

The Villages, Florida, 32162, United States

Location

Unknown Facility

Columbus, Georgia, 31909, United States

Location

Unknown Facility

Chicago, Illinois, 60640, United States

Location

Unknown Facility

Fairway, Kansas, 66205, United States

Location

Unknown Facility

Lexington, Kentucky, 40504, United States

Location

Unknown Facility

Baltimore, Maryland, 21208, United States

Location

Unknown Facility

Newton, Massachusetts, 02459, United States

Location

Unknown Facility

Plymouth, Massachusetts, 02360, United States

Location

Unknown Facility

Quincy, Massachusetts, 02169, United States

Location

Unknown Facility

Hattiesburg, Mississippi, 39401, United States

Location

Unknown Facility

Creve Coeur, Missouri, 63141, United States

Location

Unknown Facility

St Louis, Missouri, 63141, United States

Location

Unknown Facility

Princeton, New Jersey, 08540, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87109, United States

Location

Unknown Facility

Albany, New York, 12208, United States

Location

Unknown Facility

Lake Success, New York, 11042, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Staten Island, New York, 10312, United States

Location

Unknown Facility

Charlotte, North Carolina, 28270, United States

Location

Unknown Facility

Raleigh, North Carolina, 27607, United States

Location

Unknown Facility

Wilmington, North Carolina, 28401, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27157, United States

Location

Unknown Facility

Canton, Ohio, 44718, United States

Location

Unknown Facility

Shaker Heights, Ohio, 44122, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73103, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73118, United States

Location

Unknown Facility

Portland, Oregon, 97210, United States

Location

Unknown Facility

Portland, Oregon, 97225, United States

Location

Unknown Facility

Plains, Pennsylvania, 18705, United States

Location

Unknown Facility

East Providence, Rhode Island, 02914, United States

Location

Unknown Facility

East Providence, Rhode Island, 02916, United States

Location

Unknown Facility

Cordova, Tennessee, 38018, United States

Location

Unknown Facility

Dallas, Texas, 75231, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

San Antonio, Texas, 78232, United States

Location

Unknown Facility

Wichita Falls, Texas, 76309, United States

Location

Unknown Facility

Murray, Utah, 84123, United States

Location

Unknown Facility

Kirkland, Washington, 98033, United States

Location

Unknown Facility

Calgary, Alberta, T2N 4Z6, Canada

Location

Unknown Facility

Medicine Hat, Alberta, T1B 4E7, Canada

Location

Unknown Facility

Chatham, Ontario, N7L 1C1, Canada

Location

Unknown Facility

Toronto, Ontario, M3B 2S7, Canada

Location

Unknown Facility

Gatineau, Quebec, J8T 8J1, Canada

Location

Unknown Facility

Greenfield Park, Quebec, J4V 2J2, Canada

Location

Related Links

• Related Info

MeSH Terms

Conditions

Alzheimer Disease

Interventions

azeliragon

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Results Point of Contact

• Title: Ann Gooch PhD, VP Clinical Development & Regulatory Operations
• Organization: vTv Therapeutics

agooch@vtvtherapeutics.com

336-841-0300

Study Officials

• Ann Gooch, Ph.D.

  vTv Therapeutics LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 10, 2016
• First Posted: September 27, 2016
• Study Start: December 1, 2016
• Primary Completion: June 1, 2018
• Study Completion: June 1, 2018
• Last Updated: June 1, 2021
• Results First Posted: June 1, 2021

Record last verified: 2021-05

Locations

CA (6); US (65)